GlassScriptPhysician profile
Allison S Thomas
NPI 1386687028
$9,271.75
in general payments reported to CMS, 2019-2025
47 companies · $319 in 2025
The $319 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,728 · 2020: $2,213 · 2021: $2,123 · 2022: $585 · 2023: $788 · 2024: $515 · 2025: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,623.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,622.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,839.59 | 2019-2024 | Ozempic, Wegovy, Rybelsus |
| Janssen Pharmaceuticals, INC | $659.69 | 2019-2022 | |
| Pfizer INC. | $551.16 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $546.72 | 2019-2024 | Tradjenta, Jardiance |
| Astrazeneca Pharmaceuticals LP | $530.15 | 2019-2024 | Farxiga, Airsupra |
| Lilly USA, LLC | $486.78 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Allergan, INC. | $409.41 | 2019-2020 | |
| Amgen INC. | $382.57 | 2019-2024 | Prolia, Evenity, Otezla |
| Glaxosmithkline, LLC. | $312.48 | 2019-2025 | Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $309.07 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $308.49 | 2020-2025 | Rexulti |
| Abbvie INC. | $303.92 | 2021-2024 | Vraylar |
| Astellas Pharma US INC | $281.35 | 2019-2023 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $277.20 | 2019-2023 | Trintellix |
| Amarin Pharma, INC. | $273.61 | 2020-2022 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.